AstraZeneca has launched Discover, a global observational study of patients with type 2 diabetes mellitus in real world settings. This bold and ambitious non-interventional study (NIS) will be conducted in 40 countries across six continents, over the next three years and aims to recruit more than 15,000 patients with type 2 diabetes, starting a second-line anti-diabetic therapy (as add-on therapy or when switching therapies) by February 2016.
Read more... | Send to a friend
↧
New research on diabetes launches globally
↧